📰 Nasdaq Knte News
Nasdaq Knte News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Knte. Real-time updates on events, politics, business and more.
April 26, 2024
Acuitas Investments LLC purchased a new position in Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 289,766 shares of the company’s stock, valued at approximately $687,000. Acuitas Investments LLC owned approximately 0.62% of Kinnate Biopharma […]
February 24, 2024
Pale Fire Capital SE raised its stake in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) by 196.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,174 shares of the company’s stock after acquiring an additional 46,492 shares during the quarter. Pale […]
February 18, 2024
Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Free Report) has earned a consensus rating of “Hold” from the five brokerages that are covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among […]
November 27, 2023
Harvard Management Co. Inc. trimmed its stake in Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) by 7.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 462,418 shares of the company’s stock after selling 35,583 shares during the period. Kinnate Biopharma comprises approximately […]
September 21, 2023
Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) – Equities researchers at Wedbush raised their FY2023 earnings per share estimates for Kinnate Biopharma in a report released on Tuesday, September 19th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($2.23) for the year, up from their prior estimate of […]
August 17, 2023
Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) – Stock analysts at HC Wainwright increased their Q3 2023 earnings per share estimates for shares of Kinnate Biopharma in a report released on Tuesday, August 15th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.73) per share for the quarter, up from their […]
May 22, 2023
Kinnate Biopharma (NASDAQ:KNTE – Get Rating)‘s stock had its “maintains” rating reaffirmed by research analysts at 500.com in a research report issued on Thursday, Benzinga reports. Other analysts also recently issued reports about the company. The Goldman Sachs Group decreased their price target on Kinnate Biopharma from $29.00 to $26.00 and set a “buy” rating […]
May 22, 2023
500.com restated their maintains rating on shares of Kinnate Biopharma (NASDAQ:KNTE – Get Rating) in a report released on Thursday, Benzinga reports. A number of other brokerages have also commented on KNTE. Stifel Nicolaus dropped their price target on Kinnate Biopharma from $8.00 to $5.00 in a research note on Tuesday, April 18th. HC Wainwright […]
May 19, 2023
Kinnate Biopharma (NASDAQ:KNTE – Get Rating) had its price objective trimmed by HC Wainwright from $25.00 to $24.00 in a research note released on Thursday morning, The Fly reports. A number of other research analysts have also recently issued reports on the company. Wedbush reduced their price objective on Kinnate Biopharma from $25.00 to $14.00 […]
May 14, 2023
Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Rating) was the target of a significant decline in short interest in the month of April. As of April 30th, there was short interest totalling 1,510,000 shares, a decline of 16.6% from the April 15th total of 1,810,000 shares. Approximately 6.9% of the shares of the company are sold […]